J. Safra Sarasin Holding 13F: Adds $8.5M to ELV Stake
Key Points
- J. Safra Sarasin increased its holdings in Elevance Health by 22,495 shares, raising its total position to 36,832 shares valued at approximately $13.9 million.
- The fund's reported value in Elevance Health represents about 0.59% of its total 13F portfolio, ranking it 44th among 800 positions.
- Elevance Health recently traded around $431.32, showing a slight change from the closing price of $431.39 on the filing date.
Get Elevance Health text alerts
We text you when insiders, Congress, analysts or big funds move on $ELV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Elevance Health, Inc. alert may contain errors. Disclosures
J. Safra Sarasin Holding boosted its position in Elevance Health, Inc. (NYSE: ELV) by 22,495 shares, increasing its total to 36,832 shares. This move was disclosed in a filing on October 26, 2026, with a reported value of about $13.9 million.
ELV
Elevance Health, Inc.
What Changed in J. Safra Sarasin's Elevance Health Position
The fund's stake in Elevance Health increased by 156.9%, reflecting a substantial boost in its investment. The total value of this position is now approximately $13.9 million, contributing to a 0.59% share of J. Safra Sarasin's total 13F portfolio, which has a reported value of roughly $2.37 billion.
Where Elevance Health Fits in J. Safra Sarasin's Portfolio
Elevance Health ranks 44th among J. Safra Sarasin's 800 fund positions. The increase of 22,495 shares indicates a significant commitment to this stock, with an estimated gain against its cost basis still to be determined.
Other Institutional Activity in Elevance Health
In related activity, Sanders Capital, LLC holds 5,825,024 shares of Elevance Health, though it recently reduced its stake by 69,556 shares. Harris Associates L.P. increased its holdings by 128,065 shares, bringing its total to 4,924,511 shares. Artisan Partners Limited Partnership decreased its position by 546,055 shares, ending with 4,581,222 shares.
Elevance Health, Inc. Stock Down 3.1%
Elevance Health shares recently traded around $431.32, which is about equal to the closing price of $431.39 on October 26, 2026. This indicates the stock is maintaining stability around its recent trading levels.
Recent Earnings
For the trailing twelve months, Elevance Health reported revenue of approximately $201.8 billion, with an EPS of $23.55. The next earnings report is expected on January 28, 2027.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
9 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 15.1%. Revenue beat estimates by 3.1%.
-
Profit surprise
EBITDA missed by 25 percent. Operating income missed by 25 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 upgrades, 9 target raises, 1 target cut.
-
Earnings quality
Gross margin down 9.6 points. Operating margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Elevance Health delivered stronger than expected first quarter results with earnings per share of $12.58 beating the $10.68 consensus. Revenue came in at $50.2 billion, above the $48.7 billion expected. The company is executing on cost management initiatives in Medicaid and Medicare, with favorable claims experience and improved performance from AI and care delivery programs through Carelon. Management highlighted strong commercial selling momentum for 2027 with record pipelines and employer focus on affordability.
Guidance Management raised full year adjusted earnings guidance to at least $26.75 per share. They expect 2027 earnings to grow at least 12 percent from a revised 2026 baseline of $25.75. The company is confident in this outlook based on improving cost trend management and better than expected first quarter performance.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Dividend
Elevance Health pays an annual dividend of $6.88 per share, with a payout ratio of 29.2%. This dividend rate reflects the company’s commitment to returning value to its shareholders.
Insider Buying and Selling at Elevance Health, Inc.
In recent insider activity, Chief Executive Officer Gail A. Koziara Boudreaux purchased 2,725 shares on July 17, 2026, valued at approximately $1 million. Additionally, Director Ramiro G. Peru bought 1,000 shares on the same date for about $366,050. On October 22, 2026, EVP & CFO Mark Kaye sold 10,584 shares at an average price of $440.13, totaling around $4.7 million.
Analysts Set New Price Targets
On October 22, 2026, UBS maintained a "Buy" rating with a price target of $523, while Guggenheim also kept a "Buy" rating with a target of $485. Morgan Stanley maintained an "Equal-Weight" rating with a target of $449. TD Cowen set a target of $495 on October 23, 2026, maintaining a "Buy" rating.
About Elevance Health
Elevance Health, Inc. operates as a health benefits company in the United States, with a focus on providing health insurance and related services. The company operates through several segments, including Health Benefits and Carelon Services, aiming to enhance healthcare access and affordability.
Bottom Line
J. Safra Sarasin's recent position boost in Elevance Health reflects its growing confidence in the company. Investors will be watching for the next earnings report on January 28, 2027, as well as any further updates from the fund regarding its holdings.
Related Filing Alerts
Source: J. Safra Sarasin Holding's 13F filing on $ELV (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts